[THIS ARTICLE HAS BEEN RETRACTED]The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis
Author:
Corresponding Author:

Hong-Zhuo Li. Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China. lihz0999@sina.com; Shan-Shuang Du. Shaanxi Ophthalmic Medical Center, Xi’an No.4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China. sunsea2252@sina.com

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    [THIS ARTICLE HAS BEEN RETRACTED] AIM: To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis. METHODS: A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for randomized controlled trials (RCTs) comparing besifloxacin with other treatments or placebo. The primary outcome measures were clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, and bacterial eradication rates of different kinds of pathogens. Safety outcomes were the number of adverse effects (AEs). The final search was performed on August 2018. RESULTS: Eight RCTs were included. Five studies compared the efficacy and safety of besifloxacin with placebo, 2 studies compared besifloxacin with moxifloxacin, and 1 study compared besifloxacin with gatifloxacin. A total of 3105 patients met the inclusion criteria. Besifloxacin presented higher efficacy and safety than did placebo in clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, bacterial eradication rates of different kinds of pathogens and the number of AEs. There was no significant difference between besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned above. CONCLUSION: Besifloxacin is highly effective and safe for treatment of acute bacterial conjunctivitis. Further comparative trials regarding the effect of besifloxacin for treatment of acute bacterial conjunctivitis will aid in treatment decisions.

    Reference
    Related
    Cited by
Get Citation

Jun-Jie Wang, Xin-Yi Gao, Hong-Zhuo Li, et al.[THIS ARTICLE HAS BEEN RETRACTED]The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. Int J Ophthalmol, 2019,12(6):1027-1036

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:September 10,2018
  • Revised:January 23,2019
  • Adopted:
  • Online: May 06,2019
  • Published: